Evaluating Progesterone Level Fluctuations as a Response Indicator to Chemotherapy in Triple Negative Breast Cancer
DOI:
https://doi.org/10.37275/bsm.v9i7.1334Keywords:
Biomarker, Chemotherapy, Hormone levels, Progesterone, Triple negative breast cancerAbstract
Background: Triple negative breast cancer (TNBC) represents an aggressive subtype with limited targeted therapies and often poorer prognosis. Chemotherapy remains a cornerstone of treatment, yet its systemic effects, including hormonal alterations, are not fully elucidated. The role of progesterone in TNBC progression and its modulation by chemotherapy is particularly complex and warrants investigation. This study aimed to evaluate changes in serum progesterone levels following chemotherapy in TNBC patients.
Methods: A prospective cohort study was conducted at Dr. Moewardi General Hospital, Surakarta, involving 30 patients diagnosed with TNBC undergoing chemotherapy. Serum progesterone levels were quantified using the ELISA method before the first chemotherapy cycle and after the sixth cycle. Statistical analysis, primarily the Wilcoxon test, was used to compare pre- and post-chemotherapy levels.
Results: The cohort had a mean age of 49.13 ± 8.98 years. Prior to chemotherapy, progesterone levels varied: 53.3% were below normal (<0.5 ng/mL), 23.3% were normal (0.5-5 ng/mL), and 23.3% were above normal (>5 ng/mL). Following six cycles of chemotherapy, a significant decrease in progesterone levels was observed (p=0.020). The proportion of patients with below-normal levels increased to 63.3%. Overall, 10 patients showed decreased levels, 18 remained stable, and 2 showed increased levels. No significant correlation was found between progesterone level changes and baseline patient characteristics like age, menarche, or menopausal status.
Conclusion: Systemic chemotherapy significantly impacts progesterone levels in TNBC patients, leading to an overall decrease. Monitoring progesterone fluctuations during treatment may hold potential value for assessing therapeutic response or prognosis, warranting further investigation.
Authors
- Handito Sarwwotatwadhiko1*
- Widyanti Soewoto2
- Ida Bagus Budhi Surya3
- 1General Surgery Resident, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia
- 2Department of Surgical Oncology, Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia
- 3Department of Digestive Surgery, Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia
Corresponding author Handito Sarwwotatwadhiko — wadhikodito@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
